Paul M. Taslimi

Most-cited papers

1. The Structure of Dimeric ROCK I Reveals the Mechanism for Ligand Selectivity*

   M. Jacobs, K. Hayakawa, L. Swenson, S. Bellon +3 more

   2006Journal of Biological Chemistry249 citations Open access

   Semantic Scholar

   Save

2. The Discovery of VX-745: A Novel and Selective p38α Kinase Inhibitor.

   J. Duffy, Edmund M. Harrington, F. Salituro, J. Cochran +17 more

   2011ACS Medicinal Chemistry Letters88 citations Open access

   Semantic Scholar

   Save

3. Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.

   G. Bebernitz, Valerie Beaulieu, B. Dale, R. Deacon +17 more

   2009Journal of Medicinal Chemistry86 citations

   Semantic Scholar

   Save

4. Protein Complex Interactor Analysis and Differential Activity of KDM3 Subfamily Members Towards H3K9 Methylation

   Michael Brauchle, Zhiping Yao, R. Arora, S. Thigale +11 more

   2013PLoS ONE84 citations Open access

   Semantic Scholar

   Save

5. New insights into the structure-function relationships of Rho-associated kinase: a thermodynamic and hydrodynamic study of the dimer-to-monomer transition and its kinetic implications.

   J. Doran, Xun Liu, Paul M. Taslimi, Ahmad R Saadat +1 more

   2004Biochemical Journal67 citations Open access

   Semantic Scholar

   Save

6. Resveratrol inhibits firefly luciferase.

   Adel Bakhtiarova, Paul M. Taslimi, S. Elliman, P. Kosinski +3 more

   2006Biochemical and Biophysical Research Communications - BBRC65 citations

   Semantic Scholar

   Save

7. Design , Synthesis , and Structure − Activity Relationships of Pyridine-Based Rho Kinase ( ROCK ) Inhibitors

   J. Green, Jing-Rong Cao, U. Bandarage, Huai Gao +8 more

   201546 citations

   Semantic Scholar

   Save

8. Structure-based design and parallel synthesis of N-benzyl isatin oximes as JNK3 MAP kinase inhibitors.

   Jing-Rong Cao, Huai Gao, G. Bemis, F. Salituro +8 more

   2009Bioorganic & Medicinal Chemistry Letters41 citations Open access

   Semantic Scholar

   Save

9. Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.

   Ken Yamada, Julian R. Levell, Tae-Yong Yoon, D. Kohls +21 more

   2017Journal of Medicinal Chemistry35 citations Open access

   Semantic Scholar

   Save

10. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).

    L. Farmer, G. Bemis, S. Britt, J. Cochran +10 more

    2008Bioorganic & Medicinal Chemistry Letters29 citations Open access

    Semantic Scholar

    Save

11. Kinase chemogenomics: targeting the human kinome for target validation and drug discovery.

    E. ter Haar, W. Walters, S. Pazhanisamy, Paul M. Taslimi +4 more

    2004Mini-Reviews in Medical Chemistry29 citations

    Semantic Scholar

    Save

12. Abstract 2644: AP32788, a potent, selective inhibitor of EGFR and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models

    F. Gonzalvez, Xiaotian Zhu, Wei‐Sheng Huang, T. Baker +22 more

    201628 citations

    Semantic Scholar

    Save

13. Discovery of Mobocertinib, a Potent, Oral Inhibitor of EGFR Exon 20 Insertion Mutations in Non-Small Cell Lung Cancer.

    Wei‐Sheng Huang, Feng Li, Yongjin Gong, Yun Zhang +29 more

    2022Bioorganic & Medicinal Chemistry Letters23 citations Open access

    Semantic Scholar

    Save

14. Staurosporine-based binding assay for testing the affinity of compounds to protein kinases.

    G. Iyer, Paul M. Taslimi, S. Pazhanisamy

    2008Analytical Biochemistry14 citations

    Semantic Scholar

    Save

15. A gel sample block

    Paul M. Taslimi

    19921 citations

    Semantic Scholar

    Save

16. A reliable, fast, and inexpensive method of preparing sucrose density gradients

    Paul M. Taslimi, D. Kolokotronis

    19910 citations

    Semantic Scholar

    Save